Anavex Life Sciences reported a statutory loss in QQ4 2024 driven by operating expenditures and an elevated depreciation/amortization charge, with no revenue disclosed for the quarter. The company posted net income of -$11.62 million and basic earnings per share of -$0.14, alongside an EBITDA of -$34.02 million and an operating loss of -$14.34 million. Operating cash flow was negative at -$6.66 million, contributing to a net decrease in cash of -$6.57 million for the period. Notably, the balance sheet remains comfortable on a liquidity basis, with $132.19 million in cash and equivalents and no outstanding debt, yielding a robust current ratio of 8.86 and a cash ratio of 8.64. Retained earnings sit deeply negative at -$336.07 million, reflecting cumulative losses from ongoing R&D investments and clinical-stage activities. The company’s apparent liquidity runway, supported by substantial cash holdings, provides time to advance ANAVEX 273 and other candidates in mid-to-late-stage development, although the lack of near-term revenue keeps the stock highly dependent on clinical milestones and data readouts.